

Dr. Dominic Helm



Head of Proteomics Core Facility, DKFZ Heidelberg

Role in LiSyM-Cancer

- Partner in SMART-NAFLD
- Contributes access to core facility infra-structure
- Enable harmonization of clinical proteomics
- Expand the measurement capacities necessary for the analysis of large clinical cohorts

Expertise

- Expert in mass spectrometry-based prote-omics, with a strong background in method development and application specifically focusing on large scale and high-throughput experimental set-ups

Degrees

- 2012 – 2015, PhD Mass spectrometry based chemical proteomics for drug selectivity profiling, Technical University of Munich
- 2009 – 2011, Master of Science (M.Sc.), Molecular Biotechnology, Technical University of Munich
- 2006 – 2009, Bachelor of Science (B.Sc.), Biochemistry, Ulm University

Professional Experience

- Since 2025, Director Proteomics Core Facility, MD Anderson Cancer Center, Houston, Texas, United States
- 2020 – 2025, Head of Proteomics Core Facility, DKFZ German Cancer Research Center, Heidelberg
- 2016 – 2020, Senior Mass Spectrometrists in the Proteomics Core Facility at EMBL, Heidelberg
- 2015, Research Scientist at OmicScouts GmbH

Publications

2025-10-02	Multicenter evaluation of label-free quantification in human plasma on a high dynamic range benchmark set <i>Nature Communications</i>
2024-02-21	Lysis buffer selection guidance for mass spectrometry-based global proteomics including studies on the intersection of signal transduction and metabolism (preprint) <i>bioRxiv</i>
